Senores Pharmaceuticals Limited has informed the Exchange regarding Monitoring Agency Report for the quarter ended March 31, 2026
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals has submitted its Q4 FY26 Monitoring Agency Report for the Rs. 500 crore IPO (December 2024). CARE Ratings, the monitoring agency, reports that Rs. 394.98 crore (79%) has been utilized, with Rs. 105.02 crore remaining in fixed deposits. Key concern: investment in Havix subsidiary for Atlanta sterile injections facility has an ongoing delay - only Rs. 6.98 crore deployed against scheduled Rs. 40 crore for FY26 due to geo-political issues. Management extended the deadline to FY27. Two other objectives (borrowings repayment and working capital funding for subsidiaries) faced earlier delays of 25 and 43 days respectively but were completed in Q1FY26. No material deviation requiring shareholder approval was observed. All government approvals are in place.
The Atlanta facility project delay is a minor concern for investors as IPO funds remain idle (Rs. 100+ crore undeployed) while the company extends timelines. However, funds are safely parked in bank FDs, and no misuse or material deviation was found by the monitoring agency.